Regenerative medical devices company Tissue Regenix Group said it had entered into an agreement allowing Arthrex to distribute its BioRinse bone portfolio throughout Europe, with the initial focus on the UK.
The agreement built on an existing US relationship signed in March 2018.
'Since signing the US distribution agreement in March we have continued to build a strong alliance, identifying areas where we can work together and leverage the expertise of both companies,' chief executive Steve Couldwell said.
'This European agreement allows us to exploit not only our ability to import our BioRinse bone portfolio into the UK facility, but also Arthrex' expansive distribution network, another significant milestone towards our vision of building a leading force in regenerative medicine.'
At 9:19am: (LON:TRX) Tissue Regenix Group PLC share price was +0.15p at 7.4p